These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19849974)

  • 1. [Mutations in TET2 in myeloid cancers].
    Bernard OA; Delhommeau F; Fontenay M; Vainchenker W
    Med Sci (Paris); 2009 Oct; 25(10):785-8. PubMed ID: 19849974
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutation in TET2 in myeloid cancers.
    Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
    N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.
    Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M
    Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutation in TET2 in myeloid cancers.
    Tefferi A; Lim KH; Levine R
    N Engl J Med; 2009 Sep; 361(11):1117; author reply 1117-8. PubMed ID: 19741235
    [No Abstract]   [Full Text] [Related]  

  • 5. A common genetic mechanism in malignant bone marrow diseases.
    Levine RL; Carroll M
    N Engl J Med; 2009 May; 360(22):2355-7. PubMed ID: 19474434
    [No Abstract]   [Full Text] [Related]  

  • 6. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias.
    Couronné L; Lippert E; Andrieux J; Kosmider O; Radford-Weiss I; Penther D; Dastugue N; Mugneret F; Lafage M; Gachard N; Nadal N; Bernard OA; Nguyen-Khac F
    Leukemia; 2010 Jan; 24(1):201-3. PubMed ID: 19710701
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mutation of tet2 gene and malignant blood disease].
    Qian XF; Shen YF; Zhang SJ; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1096-100. PubMed ID: 20723337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cohesin complex mutations in myeloid neoplasms are enriched for SRSF2, RUNX1, TET2, and NRAS co-mutations and morphologic dysplasia.
    Hirt CK; Padmanabha N; Michaels PD
    Leuk Res; 2023 Sep; 132():107357. PubMed ID: 37481994
    [No Abstract]   [Full Text] [Related]  

  • 9. TET2 mutations in myelodysplasia and myeloid malignancies.
    Mullighan CG
    Nat Genet; 2009 Jul; 41(7):766-7. PubMed ID: 19557078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
    Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
    Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted re-sequencing of TET2 in Taiwanese patients with myelodysplastic/myeloproliferative neoplasms.
    Lin HC; Hwang DY; Lim KH
    Med Oncol; 2016 Aug; 33(8):92. PubMed ID: 27418193
    [No Abstract]   [Full Text] [Related]  

  • 12. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
    Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
    Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
    Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
    Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.
    Janssen JW; Steenvoorden AC; Lyons J; Anger B; Böhlke JU; Bos JL; Seliger H; Bartram CR
    Proc Natl Acad Sci U S A; 1987 Dec; 84(24):9228-32. PubMed ID: 3122217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.
    Mangan JK; Speck NA
    Crit Rev Oncog; 2011; 16(1-2):77-91. PubMed ID: 22150309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.
    Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA
    Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Tremblay D; Sokol K; Bhalla S; Rampal R; Mascarenhas JO
    Oncology (Williston Park); 2018 Apr; 32(4):e38-e44. PubMed ID: 29684235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
    Coltro G; Antelo G; Lasho TL; Finke CM; Pardanani A; Gangat N; Carr RM; Binder M; Mangaonkar AA; Ketterling R; Fernandez-Zapico ME; Robertson KD; Bosi A; Vannucchi AM; Tefferi A; Patnaik MM
    Am J Hematol; 2020 Apr; 95(4):E86-E89. PubMed ID: 31925810
    [No Abstract]   [Full Text] [Related]  

  • 19. Consequences of mutant TET2 on clonality and subclonal hierarchy.
    Hirsch CM; Nazha A; Kneen K; Abazeed ME; Meggendorfer M; Przychodzen BP; Nadarajah N; Adema V; Nagata Y; Goyal A; Awada H; Asad MF; Visconte V; Guan Y; Sekeres MA; Olinski R; Jha BK; LaFramboise T; Radivoyevitch T; Haferlach T; Maciejewski JP
    Leukemia; 2018 Aug; 32(8):1751-1761. PubMed ID: 29795413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.